Top Page
Tonix Pharma
(NASDAQ:TNXP)
Tonix Pharma (TNXP) vs. SPDR S&P 500 ETF (SPY)
Tonix Pharma Business Overview & Revenue Model
Tonix Pharma Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.83M | 10.09M | 7.77M | 9.03M | 0.00 | 2.91M |
| Gross Profit | 2.88M | 2.33M | 3.03M | 8.03M | -62.86M | -30.57M |
| EBITDA | -81.01M | -126.61M | -114.09M | -110.84M | -92.26M | -50.48M |
| Net Income | -53.15M | -130.04M | -116.66M | -116.88M | -92.29M | -52.17M |
Balance Sheet | ||||||
| Total Assets | 187.36M | 162.89M | 154.46M | 225.69M | 240.90M | 98.18M |
| Cash, Cash Equivalents and Short-Term Investments | 125.33M | 98.78M | 24.95M | 120.23M | 178.66M | 77.07M |
| Total Debt | 492.00K | 8.12M | 9.81M | 760.00K | 956.00K | 1.31M |
| Total Liabilities | 19.36M | 23.33M | 48.93M | 18.51M | 22.18M | 10.54M |
| Stockholders Equity | 168.00M | 139.56M | 105.53M | 207.18M | 218.72M | 87.65M |
Cash Flow | ||||||
| Free Cash Flow | -65.39M | -61.05M | -109.90M | -146.20M | -110.86M | -57.13M |
| Operating Cash Flow | -64.84M | -60.92M | -102.00M | -98.05M | -75.56M | -48.57M |
| Investing Cash Flow | -2.56M | -120.00K | -29.07M | -48.15M | -35.31M | -8.56M |
| Financing Cash Flow | 188.59M | 134.87M | 36.52M | 87.84M | 212.49M | 123.11M |
Tonix Pharma Technical Analysis
Tonix Pharma Risk Analysis
Tonix Pharma Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | $188.17M | 32.16 | 15.99% | ― | 62.79% | ― | |
| ― | $231.09M | -1.92 | -90.25% | ― | -45.35% | 96.80% | |
| ― | $198.45M | ― | -271.32% | ― | -75.77% | -31.24% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | $190.29M | ― | -52.11% | ― | -31.23% | 14.92% | |
| ― | $170.85M | ― | -77.51% | ― | -21.09% | 90.95% | |
| ― | $150.56M | -1.63 | -73.46% | ― | ― | 62.69% |
Tonix Pharma Corporate Events
On October 22, 2025, Tonix Pharmaceuticals announced that the first patient was dosed in the FOCUS study at Massachusetts General Hospital, targeting adult patients with arginine-vasopressin deficiency (AVP-D). The study is a randomized, double-blind, placebo-controlled crossover pilot designed to evaluate the company’s intranasal potentiated oxytocin products, TNX-2900 and TNX-1900, on markers of anxiety, depression, and socioemotional functioning. This trial aims to generate preliminary data for future studies on oxytocin replacement therapy, potentially impacting the treatment landscape for AVP-D and improving patient quality of life.
The most recent analyst rating on (TNXP) stock is a Hold with a $41.00 price target. To see the full list of analyst forecasts on Tonix Pharma stock, see the TNXP Stock Forecast page.
Tonix Pharmaceuticals announced plans to initiate a Phase 2 trial of its TNX-102 SL product candidate for major depressive disorder in 2026, and an adaptive Phase 2/3 study of TNX-4800 for the seasonal prevention of Lyme disease in 2027. These developments are part of the company’s strategic efforts to expand its clinical pipeline and strengthen its position in the pharmaceutical market.
The most recent analyst rating on (TNXP) stock is a Hold with a $41.00 price target. To see the full list of analyst forecasts on Tonix Pharma stock, see the TNXP Stock Forecast page.
On September 30, 2025, Tonix Pharmaceuticals announced the appointment of Ganesh Kamath as Head of Market Access, effective September 29, 2025. The company also established the wholesale acquisition cost for Tonmya™, setting it at $1,860 per month for a 60-count supply for adults, and $930 per month for a 30-count supply for geriatric patients and adults with mild hepatic impairment.
The most recent analyst rating on (TNXP) stock is a Hold with a $41.00 price target. To see the full list of analyst forecasts on Tonix Pharma stock, see the TNXP Stock Forecast page.
On September 29, 2025, Tonix Pharmaceuticals announced plans to advance its TNX-2900 program for Prader-Willi syndrome into a Phase 2 clinical trial. The trial will assess the safety, tolerability, and efficacy of TNX-2900 in children aged 8 to 17.5 years, with the study expected to start in 2026. This development marks a significant step in Tonix’s efforts to address rare diseases, potentially enhancing its market position and offering new treatment options for stakeholders.
The most recent analyst rating on (TNXP) stock is a Hold with a $41.00 price target. To see the full list of analyst forecasts on Tonix Pharma stock, see the TNXP Stock Forecast page.
On September 18, 2025, Tonix Pharmaceuticals announced the completion of a Type B Pre-IND meeting with the FDA for its TNX-102 SL product candidate aimed at treating major depressive disorder. The FDA’s feedback was positive, suggesting that the proposed long-term safety data collection plan is reasonable, which may streamline the development path. Tonix plans to file an Investigational New Drug application in the fourth quarter of 2025 and expects to enter Phase 2 clinical trials soon after, potentially expanding the therapeutic indications of TNX-102 SL.
The most recent analyst rating on (TNXP) stock is a Hold with a $41.00 price target. To see the full list of analyst forecasts on Tonix Pharma stock, see the TNXP Stock Forecast page.
On September 17, 2025, Tonix Pharmaceuticals announced the in-licensing of worldwide rights to TNX-4800, a long-acting human monoclonal antibody targeting Lyme disease. Developed by UMass Chan Medical School, TNX-4800 offers a novel approach by providing pre-exposure prophylaxis against Lyme disease with a single subcutaneous administration, bypassing the need for multidose vaccines. This strategic move positions Tonix to advance TNX-4800 through clinical trials, aiming for a Biologics Licensing Application submission to the FDA, potentially impacting the market for Lyme disease prevention.
The most recent analyst rating on (TNXP) stock is a Hold with a $41.00 price target. To see the full list of analyst forecasts on Tonix Pharma stock, see the TNXP Stock Forecast page.
Tonix Pharmaceuticals Holding Corp. is a biotechnology company focused on developing therapies for pain management and vaccines for public health challenges, with a notable emphasis on fibromyalgia treatment. In its latest earnings report for the quarter ending June 30, 2025, Tonix Pharmaceuticals highlighted a significant increase in cash and cash equivalents, totaling $125.3 million, up from $98.8 million at the end of 2024. However, the company reported a net loss of $28.3 million for the quarter, an improvement from the $78.8 million loss in the same period last year. The company’s revenue slightly decreased to $2 million from $2.2 million in the previous year, while operating expenses were reduced significantly, contributing to a smaller operating loss compared to the previous year. Tonix Pharmaceuticals continues to advance its pipeline with TNX-102 SL for fibromyalgia, which has a PDUFA goal date in August 2025, and is progressing with TNX-1500 for organ transplant rejection prevention. Looking ahead, Tonix Pharmaceuticals is focused on securing additional funding to support its operations and research initiatives, as its current cash resources are expected to sustain operations into the third quarter of 2026.
On August 18, 2025, Tonix Pharmaceuticals will host a webcast and conference call to discuss the FDA’s approval of Tonmya for fibromyalgia treatment. This approval marks a significant milestone for the company, potentially enhancing its market position and offering new opportunities for growth in the treatment of central nervous system disorders.
The most recent analyst rating on (TNXP) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Tonix Pharma stock, see the TNXP Stock Forecast page.
On August 15, 2025, Tonix Pharmaceuticals announced FDA approval for Tonmya, a treatment for fibromyalgia in adults, with availability expected in the U.S. by the fourth quarter of 2025. The approval was based on successful Phase 3 trials showing significant pain reduction and good tolerability, positioning Tonix as a key player in the fibromyalgia treatment market.
The most recent analyst rating on (TNXP) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Tonix Pharma stock, see the TNXP Stock Forecast page.